

Contents

	Preface	XV
	List of Contributors	XVII
1	Relevance of Solid-state Properties for Pharmaceutical Products	1
	<i>Rolf Hilfiker, Fritz Blatter, and Markus von Raumer</i>	
1.1	Introduction	1
1.2	Drug Discovery and Development	4
1.3	Bioavailability of Solids	6
1.4	Phases of Development and Solid-state Research	7
1.4.1	Salt Selection	8
1.4.2	Polymorph Screening	9
1.4.3	Crystallization Process Development	12
1.4.4	Formulation	13
1.4.5	Method Development	14
1.5	Solid-state and Life Cycle Management	15
1.6	Conclusions	15
	<i>References</i>	<i>17</i>
2	Thermodynamics of Polymorphs	21
	<i>Sachin Lohani and David J. W. Grant</i>	
2.1	Introduction	21
2.2	Structural Origin of Polymorphism	22
2.3	Thermodynamic Theory of Polymorphism	22
2.4	Thermodynamic Relationship Between Polymorphs: Enantiotropy and Monotropy	24
2.4.1	Energy–Temperature Diagrams	24
2.4.2	Pressure–Temperature Diagrams	28
2.4.3	Inversion of Polymorphic Behavior	30

2.5	Rules to Predict Thermodynamic Relationships Between Polymorphs	31
2.5.1	Heat of Transition Rule	31
2.5.2	Heat of Fusion Rule	31
2.5.3	Entropy of Fusion Rule	32
2.5.4	Heat Capacity Rule	32
2.5.5	Density Rule	33
2.5.6	Infrared Rule	33
2.6	Relative Thermodynamic Stabilities of Polymorphs	33
2.7	Crystallization of Polymorphs	34
2.7.1	Nucleation of Polymorphs	34
2.8	Introduction to Solvates and Hydrates	37
2.8.1	Thermodynamics of Hydrates	37
2.9	Summary	40
	<i>References</i>	41
3	Characterization of Polymorphic Systems Using Thermal Analysis	43
	<i>Duncan Q. M. Craig</i>	
3.1	Introduction – Scope of the Chapter	43
3.2	Use of Differential Scanning Calorimetry for the Characterization of Polymorphs	44
3.2.1	Principles of DSC in the Context of Polymorphism	44
3.2.2	Examples of the Uses of DSC: Characterization of Drugs, Excipients and Dosage Forms	49
3.2.3	Further Uses of DSC	54
3.3	Combined Approaches	58
3.3.1	Multi-instrument Approaches	58
3.3.2	Thermal and Crystallographic Studies	63
3.3.3	Interfaced Techniques	65
3.4	Additional Thermal Methods for the Study of Polymorphism	67
3.4.1	Thermogravimetric Analysis	67
3.4.2	Thermal Microscopy	68
3.4.3	Heat of Solution Studies	69
3.4.4	Modulated Temperature DSC	70
3.4.5	High-speed DSC	72
3.4.6	Microthermal Analysis	73
3.4.7	Thermally Stimulated Current	74
3.5	Conclusions	76
	<i>References</i>	77

4	Solid-state NMR Spectroscopy	81
	<i>Joseph W. Lubach and Eric J. Munson</i>	
4.1	Introduction	81
4.1.1	Basics of Solid-state NMR	82
4.2	Applications	82
4.2.1	Identification	82
4.2.2	Selectivity	84
4.2.3	Mobility and Dynamics	85
4.2.4	Quantitation of Forms	86
4.3	Conclusions	92
	<i>References</i>	92
5	Vibrational Spectroscopic Methods in Pharmaceutical Solid-state Characterization	95
	<i>John M. Chalmers and Geoffrey Dent</i>	
5.1	Introduction	95
5.2	Mid-infrared, Raman and THz Spectroscopy: Basic Comparison of Theory, Instrumentation and Sampling	97
5.2.1	Basic Theory	97
5.2.2	Instrumentation Brief	100
5.2.3	Sampling	104
5.2.3.1	Raman Sampling	104
5.2.3.2	Mid-infrared Sampling	105
5.2.3.3	THz Spectroscopy Sample Presentation	109
5.3	Changes of State and Solid-state Effects on Infrared and Raman Spectra	110
5.3.1	Introduction	110
5.3.2	Spectra of Gases, Liquids and Solutions	110
5.3.3	Hydrogen Bonding	111
5.3.4	Amine Salts (including Amino Acids)	114
5.3.5	Solids	115
5.3.6	Polymorphism	117
5.3.7	Enantiomers and Racemates	118
5.3.8	Tautomerism	119
5.3.9	Summary	119
5.4	Examples and Applications	119
5.4.1	Polymorphism	120
5.4.2	Hydration/Drying	126
5.4.3	Quantitative Analysis and Process Monitoring	128
5.4.4	Tablets	130
5.5	Closing Remarks	135
	<i>References</i>	136

6	Crystallography for Polymorphs	139
	<i>Philippe Ochsenein and Kurt J. Schenk</i>	
6.1	Introduction	139
6.2	Solving Difficult Crystal Structures with Parallel Experiments	140
6.3	Atropisomers and Desmotropes	144
6.4	Salts	148
6.5	Influence of Solvents	149
6.6	Isolation of a Furtive Species	153
6.7	Mizolastine Polymorphs	154
6.8	Solid Solutions	157
6.9	Structures from Powder Data	160
6.10	“Behind Every Structure There is a Crystal”	164
	<i>References</i>	165
7	Light Microscopy	167
	<i>Gary Nichols</i>	
7.1	Introduction	167
7.2	Why Use a Light Microscope to Study Solid-state Properties?	168
7.3	Polarizing Light Microscope	169
7.4	Photomicrography	170
7.5	Specimen Preparation	171
7.5.1	Permanent and Temporary Mounts	172
7.5.1.1	Permanent Mounts	172
7.5.1.2	Temporary Mounts	173
7.5.2	Preparation of Temporary Mounts	173
7.5.3	Examination of Tablets	173
7.6	Observations Using Polarized Light Microscopy	174
7.6.1	Polarized Light	174
7.6.2	Crystal Studies with Plane Polarized Light	175
7.6.3	Crystal Studies with Crossed Polarizers	177
7.6.3.1	Interference Colors	177
7.6.3.2	Extinction	179
7.6.3.3	Interference Figures	181
7.6.3.4	Compensator Plates	183
7.6.3.5	Use of Circularly Polarized Light	183
7.6.4	Crystallinity	184
7.7	Refractive Index	186
7.7.1	Measuring Refractive Indices	187
7.7.2	The Becke Test	188
7.7.3	Dispersion Staining	188
7.8	Particle Size	189
7.9	Particle Shape	190
7.10	Comparing Powder Samples	194
7.11	Thermomicroscopy	195

7.12	The Microscope as a Micro-scale Laboratory	196
7.13	Twining	197
7.14	Color and Pleochroism	199
7.15	Fluid Inclusions	201
7.16	Mechanical Properties of Crystals	203
7.17	Pseudomorphs	204
7.18	Mesomorphism	205
7.19	Identification of Contaminants and Foreign Matter	206
7.20	Conclusion	207
	References	207

8 The Importance of Solvates 211

Ulrich J. Griesser

8.1	Introduction	211
8.2	Terminology and Classification of Solvates	213
8.2.1	General Terms and Definitions	213
8.2.2	Types of Solvates	215
8.2.2.1	Stoichiometric Solvates	215
8.2.2.2	Non-stoichiometric Solvates	216
8.2.3	Classification Models of Hydrates	218
8.3	Statistical Aspects and Frequency of Solvates	219
8.4	Generation and Characterization of Solvates	222
8.5	Stability and Solubility of Solvates	224
8.6	Processing of Solvates	227
8.7	Relevance, Problems and Potential Benefits	228
8.8	Patents	229
8.9	Conclusions	230
	References	230

9 Physical Characterization of Hygroscopicity in Pharmaceutical Solids 235

Susan M. Reutzel-Edens and Ann W. Newman

9.1	Introduction	235
9.1.1	Definition of Hygroscopicity	235
9.1.2	Classification of Hygroscopic Behavior	236
9.2	Water–Solid Interactions	238
9.3	Characterizing Water–Solid Interactions	239
9.3.1	Moisture Sorption Analysis	239
9.3.2	Surface Energy Approaches	243
9.3.3	Molecular Level Approaches	244
9.3.3.1	Stoichiometric Hydrates	244
9.3.3.2	Non-Stoichiometric/Channel Hydrates	245
9.3.3.3	Isomorphic Desolvates	250

9.4	Significance of Water–Solid Interactions in Pharmaceutical Systems	251
9.4.1	Physicochemical Stability	251
9.4.2	Dissolution	252
9.4.3	Physical-mechanical Characteristics	253
9.5	Strategies for Dealing with Hygroscopic Systems	254
9.6	Conclusions	256
	<i>References</i>	256
10	The Amorphous State	259
	<i>Samuel Petit and Gérard Coquerel</i>	
10.1	Introduction	259
10.2	Definition of the Amorphous State	260
10.2.1	Order, Disorder and Structural Aspects	260
10.2.2	Energetic Aspects: Thermodynamics and Kinetics	262
10.3	Preparation of Amorphous Solids	263
10.3.1	Preparation from a Liquid Phase: Quench-cooling	264
10.3.2	From a Solution: Rapid Precipitation	265
10.3.3	From a Frozen Solution: Freeze-drying (Lyophilization)	265
10.3.4	From an Atomized Solution: Spray-drying	266
10.3.5	From a Crystalline Phase: Grinding and Milling	266
10.3.6	From a Crystalline Solvate: Desolvation/Dehydration	268
10.3.7	Physical Mixture with Amorphous Excipients	269
10.4	Properties and Reactivity	269
10.4.1	The Glass Transition	270
10.4.2	Molecular Mobility and Structural Relaxation	271
10.4.3	Strong/Fragile Classification of Angell	272
10.4.4	Mixing with Solvents/“Dissolution” Behavior	273
10.4.5	Influence of Water Content: Plasticization and Chemical Degradation	274
10.4.6	Polyamorphism	275
10.5	Characterization and Quantification	276
10.5.1	Thermal Analysis and Spectroscopic Methods	277
10.5.2	Detection and Quantification of Small Amorphous Contents	277
10.6	Crystallization of Amorphous Solids	278
10.6.1	“Difficult-to-crystallize” Compounds	279
10.6.2	Inadvertent Crystallization	280
10.6.3	Crystallization as a Tool for Insight into the Amorphous State	280
	<i>References</i>	282

11	Approaches to Polymorphism Screening	287
	<i>Rolf Hilfiker, Susan M. De Paul, and Martin Szelagiewicz</i>	
11.1	Introduction	287
11.2	Crystallization Methods	289
11.3	Solvent Parameters	290
11.4	Systematic Polymorphism Screening	291
11.5	High-throughput Methods	294
11.6	An Example of a High-throughput Screening Approach	296
11.6.1	Model Substance	296
11.6.2	Solubility	296
11.6.3	Crystallization Experiments	297
11.6.4	Data Acquisition	297
11.6.5	Data Analysis	298
11.7	Theoretical Methods	300
11.8	Characterization	302
11.9	Conclusions	303
	<i>References</i>	<i>305</i>
12	Salt Selection	309
	<i>Peter Heinrich Stahl and Bertrand Sutter</i>	
12.1	Introduction	309
12.2	Salt Formation and Polymorphism	309
12.3	Target Properties of Active Substances for Drug Products	311
12.3.1	Injectables	311
12.3.2	Solid Dosage Forms	312
12.3.3	Dosage Forms for Other Routes of Application	312
12.3.3.1	Inhalation	312
12.3.3.2	Topical Products and the Transdermal Route	313
12.4	Basics of Salt Formation	314
12.4.1	Ionization Constant	314
12.4.2	Ionization and pH	315
12.4.3	Solubility	316
12.5	Approaches to Salt Screening	319
12.5.1	Initial Data	319
12.5.2	Selection of Salt Formers	319
12.5.3	Automated Salt Screening	320
12.6	Selection Procedures and Strategies	322
12.6.1	Points to be Considered	322
12.6.2	Final Decision	323
12.6.3	Salt Form and Life Cycle Management of Drug Products	325
12.7	Case Reports	325
12.7.1	Overview of Salt Forms Selected	325
12.7.2	Salt Selection Process	325
12.7.3	Case 1: NVP-BS001	326

- 12.7.4 Case 2: NVP-BS002 327
- 12.7.4.1 Discussion and Decision 329
- 12.7.5 Case 3: NVP-BS003 329
- References* 332

13 Processing-induced Phase Transformations and Their Implications on Pharmaceutical Product Quality 333
Ramprakash Govindarajan and Raj Suryanarayanan

- 13.1 Introduction 333
- 13.2 Processing-related Stress 336
 - 13.2.1 Mechanical Stress 337
 - 13.2.1.1 Milling 337
 - 13.2.1.2 Compression 337
 - 13.2.2 Thermal and Pressure Stresses 338
 - 13.2.2.1 Freezing 338
 - 13.2.2.2 Drying 339
 - 13.2.2.3 Melting 340
 - 13.2.3 Interaction with Other Components 341
 - 13.2.3.1 Hydrate Formation 341
 - 13.2.3.2 Complexation 342
 - 13.2.3.3 Salt-Free-acid/Base Conversions 342
 - 13.2.3.4 Metastable Phase Formation 342
 - 13.2.3.5 Multiple Interactions 343
- 13.3 Detection and Quantification of Phase Transformations 343
 - 13.3.1 Generation (Creation) of Lattice Disorder 343
 - 13.3.2 Crystallization – Anhydrous Phase 347
 - 13.3.3 Hydrates – Formation and Dehydration 349
 - 13.3.4 Salt-Free-acid/Base Transformations 351
- 13.4 Implications of Phase Changes 352
 - 13.4.1 Amorphization 352
 - 13.4.2 Crystallization 356
 - 13.4.3 Polymorphic Transitions 357
 - 13.4.4 Hydration/Dehydration 358
 - 13.4.5 Salt-Free-acid/Base Conversion 360
- 13.5 Summary 360
- References* 361

14	Polymorphism and Patents from a Chemist's Point of View	365
	<i>Joel Bernstein</i>	
14.1	Introduction	365
14.2	Some Fundamentals of Patents Related to Polymorphism and Some Historical Notes	366
14.3	Ranitidine Hydrochloride (RHCl)	369
14.4	Cefadroxil	372
14.5	Paroxetine Hydrochloride	375
14.6	The Importance of Seeding	379
14.7	Concluding Remarks	381
	<i>References</i>	382
15	Scientific Considerations of Pharmaceutical Solid Polymorphism in Regulatory Applications	385
	<i>Stephen P. F. Miller, Andre S. Raw, and Lawrence X. Yu</i>	
15.1	Introduction	385
15.2	General Principles of Pharmaceutical Solid Polymorphs	385
15.3	Influence of Polymorphism on Product Quality and Performance	386
15.3.1	Effect on Bioavailability (BA)/Bioequivalence (BE)	386
15.3.2	Effect on Stability	387
15.3.3	Effect on Manufacturability	388
15.4	Pharmaceutical Solid Polymorphism in Drug Substance	389
15.4.1	Polymorph Screening	390
15.4.2	Control of Polymorphism in Drug Substance	391
15.4.3	Acceptance Criterion for Polymorph Content in Drug Substance	394
15.5	Pharmaceutical Solid Polymorphism in Drug Product	395
15.5.1	Polymorphism Issues in Drug Product Manufacturing	395
15.5.2	Control of Polymorphism in Drug Product	396
15.6	Process Analytical Technology	399
15.6.1	Process Analytical Technology and the Crystallization of Polymorphic Forms	399
15.6.2	Process Analytical Technology and Polymorphs in Drug Products	400
15.7	Summary	401
	<i>References</i>	402
	Subject Index	405

